Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Treatment of Patients With BRCA Mutated Pancreatic Cancer: The Clinical Perspective

Learn how to personalize therapy to molecular subtypes of pancreatic cancer including malignancies with defective DNA repair, immunogenic signatures, and rare genetic abnormalities such as NTRK and NRG1 fusions.
person default
Dirk Arnold, MD, PhD
Michael J. Pishvaian, MD, PhD
Released: October 8, 2020

This program is divided into several short segments which you can step through using the Video Chapters widget.

Information on this Educational Activity

Faculty

Dirk Arnold, MD, PhD

Professor of Oncology
University of Hamburg
Director
Department of Oncology
AK Altona
Asklepios Tumorzentrum Hamburg
Hamburg, Germany

Dirk Arnold, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Pierre Fabre, and Roche; funds for research support from AstraZeneca, Bristol-Myers Squibb, and Pierre Fabre; fees for non-CME/CE services from Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Pierre Fabre, and Roche; and other financial or material support from AstraZeneca.
Michael J. Pishvaian, MD, PhD

Associate Professor
Department of Gastrointestinal Medical Oncology
Co-director for Clinical Research
Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
The University of Texas MD Anderson Cancer Center
Houston, Texas

Michael J. Pishvaian MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Caris, Celgene, Halozyme, Ipsen, MedImmune, Merck, Merrimack, Perthera, Rafael, RenovoRx, and Sirtex; has received funds for research support from Armo, AstraZeneca, Bavarian Nordic, Bayer, Boston Biomedical, Bristol-Myers Squibb, Calithera, Celgene, Celldex, Curegenix, FibroGen, Genentech, Gilead Sciences, GlaxoSmithKline, Halozyme, Karyopharm, MedImmune, Merck, Novartis, Pfizer, Pharmacyclics, Regeneron, and Tesaro; and has ownership interest in Perthera.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Target Audience

This program is intended for medical oncologists and other healthcare providers who care for patients with pancreatic cancer globally.

Goal

The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with pancreatic cancer.

Program Medium

This program has been made available online.

Related Content

Expert commentary on the use of PARP inhibitors in the treatment of pancreatic cancer, from Clinical Care Options

person default Dirk Arnold, MD, PhD Released: October 30, 2020

Latest data and expert guidance on targeting KRASG12C for treatment of solid tumors from Clinical Care Options (CCO)

Marwan Fakih, MD Released: October 29, 2020

Latest data and expert guidance on targeting KRASG12C for treatment of solid tumors in an online activity and a downloadable slideset from Clinical Care Options (CCO)

Marwan Fakih, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: October 29, 2020 Expired: October 28, 2021

Video Chapters


Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue